Loading...
XOSLPCIB
Market cap4mUSD
Dec 23, Last price  
1.30NOK
1D
-1.52%
1Q
-30.85%
Jan 2017
-90.66%
IPO
-86.45%
Name

PCI Biotech Holding ASA

Chart & Performance

D1W1MN
XOSL:PCIB chart
P/E
—
P/S
16.23
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.65%
Rev. gr., 5y
-2.15%
Revenues
3m
7,367,0008,612,00010,444,0007,423,000000000000002,990,000
Net income
-20m
L-62.20%
-11,375,000-15,015,000-13,940,000-13,749,000-25,259,000-27,608,000-35,840,000-31,922,000-32,184,000-42,841,000-34,780,000-89,252,000-72,636,000-88,480,000-53,743,000-20,315,000
CFO
-15m
L-74.65%
-9,409,000-16,836,000-10,591,000-19,049,000-24,354,000-28,593,000-31,674,000-32,841,000-35,693,000-30,620,000-31,079,000-83,471,000-77,391,000-68,307,000-59,042,000-14,970,000
Earnings
Feb 13, 2025

Profile

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
URL
https://www.pcibiotech.no/
IPO date
Jun 18, 2008
Employees
6
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,990
 
Cost of revenue
25,231
61,830
94,843
Unusual Expense (Income)
NOPBT
(22,241)
(61,830)
(94,843)
NOPBT Margin
Operating Taxes
(1,352)
89
Tax Rate
NOPAT
(22,241)
(60,478)
(94,932)
Net income
(20,315)
-62.20%
(53,743)
-39.26%
(88,480)
21.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
319
443
629
Long-term debt
319
1,097
3,183
Deferred revenue
Other long-term liabilities
33
Net debt
(40,545)
(54,427)
(111,368)
Cash flow
Cash from operating activities
(14,970)
(59,042)
(68,307)
CAPEX
(341)
Cash from investing activities
(341)
Cash from financing activities
(442)
(678)
(673)
FCF
(20,963)
(54,393)
(94,598)
Balance
Cash
41,183
55,967
115,180
Long term investments
Excess cash
41,034
55,967
115,180
Stockholders' equity
1,119
57,402
(336,671)
Invested Capital
38,276
2,206
452,369
ROIC
ROCE
EV
Common stock shares outstanding
37,326
37,326
37,326
Price
2.10
2.44%
2.05
-85.26%
13.91
-50.14%
Market cap
78,385
2.44%
76,518
-85.26%
519,205
-50.09%
EV
37,840
22,091
407,837
EBITDA
(21,870)
(55,424)
(92,302)
EV/EBITDA
Interest
160
127
89
Interest/NOPBT